S100B and melanoma: These data correspond with previous findings that elevated S‐100B was the only sign in 20% of patients with disease progression.16 In the present series, 33% of patients that recurred IV disease had increased S‐100B, which is in line with prior reports of increased S‐100B levels in 4% to 100% of patients with stage IV disease.6 In stage II and III melanoma patients, the reported sensitivity and specificity of S‐100B for recurrent disease varies from 29% to 43% and 93% to 94%, respectively.7, 11, 18